RPGLIFE2,780.00

RPG Life Sciences Limited

· Pharma & Health
AnnualQuarterly₹ CrorePeersGUFICBIOGUJTHEMUNICHEMLABORCHPHARMASMSPHARMAFDCIOLCPINDSWFTLABMcap ₹4,597 Cr
View
In ₹ Crore except Per Share
12 Months Ending
Q3 FY26
31/12/2025
Q4 FY26
31/03/2026
Q1 FY27
30/06/2026
Revenue from Operations180.0176.9195.7
Other Income3.412.44.7
Total Income183.4189.3200.4
Expenses
+ Cost of Materials Consumed34.836.437.7
+ Purchases of Stock-in-Trade43.622.639.5
+ Changes in Inventories-13.51.5-9.1
+ Employee Benefit Expense35.336.337.8
+ Finance Costs0.30.40.6
+ Depreciation & Amortisation5.45.75.9
+ Other Expenses40.147.246.5
Total Expenses145.9150.2158.9
EBITDA39.832.843.3
EBIT34.427.137.4
Profit
PBT before Exceptional Items37.539.141.5
+ Exceptional Items-8.41.10.0
Pretax Income29.140.241.5
+ Current Tax6.97.210.8
+ Deferred Tax0.13.1-0.1
Tax Expense7.010.310.7
Net Income22.129.930.8
+ Net Income — Continuing Ops22.129.930.8
+ Other Comprehensive Income-0.70.1-0.2
Total Comprehensive Income21.530.030.6
Per Share
Basic EPS13.3818.0818.60
Diluted EPS13.3818.0818.60
Other Comprehensive Income — detail
+ Other Comprehensive Income-0.70.1-0.2
+ Items NOT to be Reclassified to P&L-0.90.1-0.2
+ Tax on Items NOT to be Reclassified-0.20.0-0.1
Per Share — as-filed variants
Basic EPS — Continuing Operations13.3818.0818.60
Diluted EPS — Discontinued Operations13.3818.0818.60
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit115.1116.3127.5
Gross Margin %63.9565.7565.17
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)37.539.141.5
− Exceptional Items (reconciliation)-8.41.10.0
Net Income Adj (tax-effected)28.529.130.8
EPS Adj17.2517.5918.60
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value10.008.008.00
Paid Up Equity Capital13.213.213.2
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.